# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## FORM 8-K

#### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 15, 2024

# Longboard Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation) 1-40192 (Commission File Number)

4275 Executive Square, Suite 950 La Jolla, CA (Address of Principal Executive Offices) 84-5009619 (IRS Employer Identification No.)

> 92037 (Zip Code)

Registrant's Telephone Number, Including Area Code: (858) 789-9283

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

D Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Derecommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value \$0.0001 per share	LBPH	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  $\boxtimes$ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

#### Item 7.01 Regulation FD Disclosure.

Included as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is a poster titled "Efficacy and Safety of Bexicaserin (LP352) in Adolescent and Adult Participants with Developmental and Epileptic Encephalopathies: Results of the Phase 1b/2a PACIFIC Study" (the "Poster"). Longboard Pharmaceuticals, Inc. (the "Company") is scheduled to present the Poster at the 76th Annual Meeting of the American Academy of Neurology on April 15, 2024. The Company also expects to use the contents of the Poster in various meetings and presentations with securities analysts, investors and others beginning on April 15, 2024.

The Company also plans to make the Poster available on its website (http://www.longboardpharma.com), on the page titled "Our Approach," under the heading "Publications."

Information contained in, or that can be accessed through, the Company's website is not incorporated by reference into this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly stated by specific reference in such filing.

#### Item 9.01 Financial Statements and Exhibits. (d) Exhibits.

Exhibit No.	Description
99.1	Longboard Pharmaceuticals poster titled "Efficacy and Safety of Bexicaserin (LP352) in Adolescent and Adult Participants with Developmental and
	Epileptic Encephalopathies: Results of the Phase 1b/2a PACIFIC Study"
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Longboard Pharmaceuticals, Inc.

Date: April 15, 2024

By: /s/ Kevin R. Lind Kevin R. Lind

President and Chief Executive Officer

EFFICACY AND SAFETY OF BEXICASERIN (LP352) IN ADOLESCENT AND ADULT PARTICIPANTS WITH DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES: RESULTS OF THE PHASE 1B/2A PACIFIC STUDY

A LOT 

#### BACKGROUND

Control Contr

### OBJECTIVE

To assess the safety, tolera in participants with DEEs.

#### T METHODS

Starty Desting
 This was a reader to a start of the start of t

Vey restruction there a measure of the set o

Screening Period	Treatment Period				
	Randomization and Up-Titration	Maintenance*	Down- Titration	Follow-up Period	
S Weeks	Dava 1-16	Days 16-25	Days 76-60750-	30 Days	
		nicaserin (n = 43)			
	šme → time → lũ me	Darticipent versioned on 6.9, or 12 mg speed on specificity during up-doubtion			Open-La Extensi

	Dravet Syndrome		DEE Other	
Onset	Between 3-19 months of age	Before B years of age	Unprovoked settares locfore 5 years of age	
Seloure Type	Generalized tonio-clonic, unisteral clonic, or bilateral clonic seizures	Tonic or toniciatonic solaans and more than 1 type of generalized setzure (tonic, storic, tonic, tanic attrict, attrict, tonic, mysoclonic, or drop!	Combined focal and generalized seizure type or multiple generalizer seizure types	
Dovelopmental History	Initially normal, then delayed	Delayed	Dolayed	
Bectroencephalography		Consistent with LCS diagnosis*	Sion or disorganized	
Additional Criterio	One of the following	More than I type of generalited seiture for 26 months before screening	No history of idepathic generalized sectores	

Participants					
52 participants (43 besicaserin, 9) Syndrome, and 19 DEE Other) ac	olacebo) were randomly ross 34 sitos ( <b>Tables 2</b> :	assigned to treatment and 3)	t (29 LGS, 4 Dravet		
Table 2. Participant Dispo	sition				
Parameter n (%)	meakaserin ja = 43)		Ptaceba (n = 9)		
Safety-set	43 (100)		9 (900)		
Full analysis set	55 (91.4)		9 (100)		
Participants complexed	32 (7)./2		9 1001		
Min.mat	12, 55	12, 41	10,55		
Age, mean (SD), years	23.0 (9.63) 12,55	26.7 (773) 13, 41	74.5 (9.3) 72,55		
Sex, n Né Halo Female	23 (40.0) 72 (51.7)	7 (7700) 7 (720)	20 (53.0) 24 (46.2)		
Sex n No Male			24 (46.2)		
Sex, n Nû Hale Female	22 (51.7)	2 (72.2)			

 35 participants received [12 mg TiD) and 27 (77.9) period (Table 4)
 Table 4. Highest Tol Maintenance Period d Dose Achieved and Maintained for the Mainte n(%) Al partice 6 mg 9 mg 12 mg Matchie 9 44 0 4 (ki) 1 (ki) 5 (li4) 0 (ki) 1 35 (70.5)

 Cmp
 200%
 BLBR
 30,001

 Stafpy
 Build Staff
 30,001
 BLBR
 30,001

 \* The most common TLASE uses providence, devised appointer, constrained appointer, during strategistic constrained appointer
 Manual Market Staff
 Manual Market Staff

 \* The provide strategistic constrained appointer
 Manual Market Staff
 Manual Market Staff
 Manual Market Staff

 \* The provide strategistic constrained appointer
 Market Staff
 Manual Market Staff
 Manual Market Staff


 \* During the Instrument provide XI of the biocessmin encomposition date Staff
 Manual Market Staff
 Manual Market Staff

 \* During the Instrument provide XI of the biocessmin encomposition date Staff
 Manual Market Staff
 Manual Market Staff


Placebo 1 0.003


Porticipants with 21 te 48	35 (21.4)	8,98.%	45 (92)1
TEADs by SOCI			
Nervous system disorders			
Samolence	12 (273)	1 (12)	13 (25.0)
Lethergy	6(0.2)	0	4 (27)
Tremor	300	0	3 (5.8)
Gastrointesting! disorders			
Constitution	6 (34.0)	0	6 (1.5)
Diamhoo	5 (0.6)	0	5 (9.6)
infections and infestations			
Urinery tract infection	3 (7.0)	0	3 (5.8)
General disorders and administration size conditions			
Fatigue	300	0	35.0
Pyrexia	300	0	3 (5.0)
Motabolism and nutrition disorders			
Decreased appetite	9 (20.9)	0	9 (77.3)
Peychiatric disordance			
Agitation	3 (2.0)	0	35.8
Vescular disorders			
Hypotension	300	0	35.8

A	0-	Bexicaserin	Placebo	В	24-1	Beckaserin	Placebo
8	-10-4			2	150		
Left of	-20		-17.4%	t is	100		
2.2	-10-			şa	75		
1 Ce				100	14- 25-		
88					0		-
100	~50	-59.8%		200	-20		- T
				- 6	-73	+	









CONCLUSIONS ated in participants with a polytherapy multiple antiseizure medications, includi

Abbreviations 5-HT, S-hydroxy typteming AE, advece event, BML body mass index, DEE, Developmental and TpReptic through-logathy, LSS, Lemons-Castad Syndrome SAE, sectors advece event SD, standard deviator, SOE, system organ clas TAE, troatenets enregient advecement event; TB, S, times claby.

plaguas 2009/8010, 2013, Korelwer JF, Land L, Pol Dewolfen Assen, 2013 AM, S. Linkoph Kei, al. (Paphyse Anton, 2014) AM in a Conference on Sec. 2013 SIM MIL E-Margin (Conf. 2014) AM INFORMATION CONFERENCE CONFERENCE CONFERENCE OF Internet angles and the AC Internet and the AC Internet Conference on Sec. 2014 SIM INFORMATION CONFERENCE OF Internet angles and the AC Internet American and the AC Internet Conference on Sec. 2014 AM INFORMATION CONFERENCE ON A INFORMATION Internet angles and the AC Internet American and the AC Internet Conference on Sec. 2014 SIM INFORMATION CONFERENCE ON A INFORMATION Internet angles and the AC Internet American and the AC Internet Conference on Sec. 2014 SIM INFORMATION CONFERENCE ON A INFORMATION OF A INFORM